On Friday, Rafael Holdings Inc (NYSE: RFL) stock price moved down at -2.18%. Its total market capitalization is $275389384. Its day lowest price was $19.5 and its hit its day highest price at $20.88. The stock recent volume is 109202 shares in comparison to its average trading volume of 59943 shares. Looking at the stock’s price level on the past 52-week graph, RFL recorded a 52-week high of $30.86 and its 52-week low of $6.9.
Rafael Holdings, Inc., (RFL) stated revenue of $4.9M and a loss per share of $0.35 for the fiscal year ended July 31, 2019. Fourth quarter revenue was $1.4M and the loss per share was $0.16.
Recent Operational Highlights
- Rafael Pharmaceuticals, a clinical-stage pharmaceutical company in which the Company holds preferred equity and a warrant to increase ownership to 56% of the fully diluted equity interests, reached an out-licensing contract with Ono Pharmaceutical Co., Ltd. of Japan. Ono gained exclusive rights to develop and commercialize Rafael Pharma’s lead drug candidate, CPI-613® (devimistat) and related compounds for all indications in certain Asia-Pacific region countries. Rafael Pharma received an upfront payment of $12.9M, with the right to an additional $150.3M contingent on attainment of certain developmental and commercial milestones. Rafael Pharma will also receive low-double digit royalties based on net sales.
- Rafael Pharma continued to expand its pivotal Phase 3 trial of CPI-613® (devimistat) for patients with relapsed or refractory acute myeloid leukemia (AML) adding clinical trial sites in France, Austria, South Korea and Spain.
- Rafael Pharma continued to expand its pivotal Phase 3 trial of CPI-613® (devimistat) in combination with modified FOLFIRINOX as a first-line treatment for patients with metastatic pancreatic cancer adding clinical trial sites in France, Korea and Israel.
Remarks by Howard Jonas, Chairman and CEO of Rafael Holdings
“During the fourth quarter, our key pharma holding, Rafael Pharma, continued to advance its clinical development programs, including pivotal, multi-jurisdictional, Phase 3 trials of CPI-613® (devimistat). Rafael Pharma also reached an out-licensing contract with Ono Pharmaceuticals reflecting the promise of Rafael Pharma’s lead drug candidate.
“In addition, we have established a wholly-owned venture to develop a pipeline of therapeutic compounds including compounds to regulate cancer metabolism. The venture is pursuing collaborative research contracts with scientists from top academic institutions.
“We also continue our efforts to realize the value of our real estate holdings including our 20-story commercial property and associated garage in Newark, New Jersey.”
RFL has been recorded -1.95% away from 50 day moving average and 14.69% away from 200 day moving average. Moving closer, we can see that shares have been trading -3.52% off 20-day moving average.
Zachary Harrison – Healthcare Reporter
I am an outstanding Healthcare writer, and analyst. Before I joined News Billion, I already was a well-known business analyst. I wrote an analysis of the market for famous financial outlets. My research articles were easy to understand, full of details and objective. I believe that every community, regardless of size, deserves top-notch news coverage from my online news portal. That principle guides the decisions I makes in daily news coverage.
Mailing address: 936 Watkins Farm Road, Nicholson, GA 30565, USA
Zip code: 30565
Phone number: 517-788-1142
Email: [email protected]